Welcome to our dedicated page for IDEX /DE/ SEC filings (Ticker: IEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IDEX /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IDEX /DE/'s regulatory disclosures and financial reporting.
IDEX Corporation announced that Sean M. Gillen will become Senior Vice President and Chief Financial Officer effective January 5, 2026, succeeding interim CFO Akhil Mahendra, who will return to his role as Vice President, Corporate Development. Gillen joins from AAR CORP., where he has been Senior Vice President and CFO since 2019, and previously held finance and investment banking roles at USG Corporation and Goldman Sachs.
Under an offer letter dated December 1, 2025, Gillen will receive a base salary of $625,000, target annual cash incentive equal to 85% of base salary starting with the 2026 program, and an annual equity grant targeted at $2,000,000. He will also receive a one-time restricted stock award valued at $3,000,000 that vests over three years and a cash sign-on bonus of $325,000, subject to repayment if he departs or is terminated for cause within 12 months. Severance protections include one year of base salary and target bonus if terminated without cause, increasing to two times those amounts if this occurs within 24 months after a change in control. IDEX also disclosed that Melissa S. Flores, Senior Vice President and Chief Human Resources Officer, will resign effective December 19, 2025 to pursue another opportunity.
IDEX Corporation (IEX) filed a Form 4 reporting an insider purchase. A company director bought 600 shares of common stock on 11/05/2025 at a weighted average price of $169.4112. Following the transaction, the director beneficially owns 6,351 shares, held directly.
The filing notes the trade was executed in multiple lots with prices ranging from $169.35 to $169.43. The weighted average reflects those individual executions, and the reporting person undertakes to provide the specific trade breakdown upon request.
IDEX Corporation (IEX) reported higher quarterly results. For the three months ended September 30, 2025, net sales were $878.7 million, up from $798.2 million, with operating income of $185.8 million versus $168.0 million. Diluted EPS was $1.70 compared with $1.57 a year ago.
Nine-month results were mixed: net sales rose to $2,558.4 million from $2,405.9 million, while net income attributable to IDEX was $354.9 million versus $381.8 million, and diluted EPS was $4.70 versus $5.02. Operating cash flow reached $470.9 million. The company repurchased $175.0 million of common stock year to date and declared a quarterly dividend of $0.71 per share.
Health & Science Technologies led growth, with Q3 revenue of $380.1 million (from $309.9 million), aided by acquisitions. IDEX completed the acquisition of Micro‑LAM for total consideration of $81.9 million and ended the quarter with cash and cash equivalents of $593.8 million and total borrowings of $1,911.8 million, including $310.6 million drawn on its revolving facility.
IDEX Corporation furnished an Item 2.02 Form 8‑K announcing quarterly results for the period ended September 30, 2025. The company issued a press release, provided as Exhibit 99.1, on October 29, 2025. This information is being furnished and is not deemed filed under the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL tags.
IDEX Corporation disclosed that its Board of Directors authorized an additional $635 million for repurchases of the company’s common shares. When combined with approximately $365 million remaining under prior authorizations, the company now has a total share repurchase authorization of about $1 billion.
The company states that repurchases may occur from time to time through open market or privately negotiated transactions and may also be executed under Rule 10b5-1 plans. Management will determine the timing, volume and nature of repurchases based on market conditions, cash investment priorities, applicable securities laws and other factors, and the program can be suspended or discontinued at any time.
Helmkamp Katrina L, identified as a director of IDEX Corporation (IEX), purchased 2,500 shares of common stock on 08/07/2025 at a weighted average price of $159.6104 per share, in multiple trades priced between $159.51 and $159.65. After the reported acquisition, the reporting person beneficially owns 13,200 shares directly.
The Form 4 shows no derivative transactions in Table II. A footnote states the transaction was executed in multiple trades and that the reporting person will provide detailed per-trade quantities and prices upon request.